Loading stock data…
DaVita Inc. (DVA)
$183.01+2.95 (+1.64%)
Market ClosedLast close Sep 9
DaVita Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
DaVita Inc. in the Healthcare sector is trading at $183.01 with a market capitalization of $11.2B. Wall Street consensus targets $218.43 (7 analysts), implying a +19.4% move over the next 12 months. The stock is currently 26% below its 52-week high of $247.49, remaining 11.1% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +19.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.55B↑ | $3.42B↓ | $3.62B↑ | $3.42B↑ | $3.38B |
| Gross Profit | $1.16B↑ | $1.07B↓ | $1.21B↑ | $1.09B↓ | $1.12B |
| Operating Income | $570.82M↑ | $473.55M↓ | $551.21M↑ | $495.61M↓ | $530.48M |
| Net Income | $265.40M↑ | $197.53M↓ | $234.22M↑ | $150.33M↓ | $199.34M |
Peer Comparison
JNJUNHPFE
Fundamentals
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$11.23B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
15.32
Beta
Defensive asset. Lower volatility than the S&P 500.
0.87
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-110.77%
Volume
Today's trading volume
688,637
Recent News
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
DVA gains from expanding value-based kidney care, improving dialysis volumes and clinical innovation, though payer-mix and regulatory risks persist.
3 Reasons to Sell DVA and 1 Stock to Buy Instead
DaVita’s 20.6% return over the past six months has outpaced the S&P 500 by 7%, and its stock price has climbed to $183.98 per share. This performance may have investors wondering how to approach the situation.
Why Is Encompass Health (EHC) Down 1.8% Since Last Earnings Report?
Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 of Wall Street’s Favorite Stocks We Find Risky
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
DaVita (DVA) Has Investors Asking A Fresh Question
DaVita (DVA) is back in focus after two meaningful developments. The company expanded its value based care partnership with Humana for chronic kidney disease patients and agreed to a US$15 million settlement related to a prior data breach. Investors have been reacting to this mix of partnership news and legal resolution with a share price that is still up 58.64% year to date, despite a 30 day share price return of down 20.32%. The 3 year total shareholder return of 90.54% points to momentum...